SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

Sanofi (SNY) announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab).With this nod, Sarclisa is now approved, in combination with Velcade (bortezomib) and Bristol Myers’ (BMY) Revlimid (lenalidomide) and dexamethasone (“VRd”), for the treatment of patients with newly diagnosed MM (NDMM) who are not eligible forautologous stem cell transplant.This approval was expected as the EMA’s Committee for Medicinal Pro ...